Table 2 Outcomes at 24 months after treatment.

From: Diabetic macular edema and proliferative diabetic retinopathy treated with anti-vascular endothelial growth factor under the reimbursement policy in Taiwan

 

Gr 1 N = 41

Gr 2 N = 43

p

IVI (times)

12.02 ± 6.57

11.89 ± 4.86

0.91

logMAR BCVA

0.47 ± 0.41

0.47 ± 0.37

0.96

Delta logMAR BCVA

− 0.13 ± 0.37

− 0.09 ± 0.33

0.65

CRT

319.51 ± 133.52

309.67 ± 90.95

0.69

Delta CRT

− 106.51 ± 194.87

− 104.21 ± 114.89

0.95

DRIL

304.02 ± 271.57

295.28 ± 277.09

0.88

New VH

9/41

14/43

0.33

VH that requested PPV

2/41

4/43

0.68

New ERM

3/41

8/43

0.20

ERM

11/41

15/43

0.48

Pseudophakia

15/41

17/43

0.83

Supp. PRP rates

9/41

19/43

0.04

SMPL rates

2/41

11/43

0.01

FRP rates

2/41

5/43

0.43

MAs

64.90 ± 30.81

86.13 ± 53.10

0.06

NV

0.05 ± 0.23

0.14 ± 0.68

0.47

NVI

0/41

1/43

1.00

NVG

1/41

5/43

0.20

Endophthalmitis

0/41

1/43

1.00

RRD

1/41

0/43

0.49

TRD

0/41

1/43

1.00

  1. IVI intravitreal injection, VH vitreous hemorrhage, ERM epiretinal membrane, supp. Supplementary, PRP panretinal photocoagulation, SMPL subthreshold micropulse laser, logMAR BCVA best-corrected visual acuity in the logarithm of the minimal angle of resolution, CRT central retinal thickness, DRIL Disorganization of the retinal inner layers, NVI neovascularization of iris, NVG neovascular glaucoma, RRD rhegmatogenous retinal detachment, TRD tractional retinal detachment, PPV pars plana vitrectomy, MAs microaneurysms, NV retinal neovascularization.
Back to article page